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Liver disease associated with persistent hepatitis B virus 
(HBV) infection remains an important public health prob-
lem with significant morbidity and mortality. In spite of 
the existence of an effective vaccine, worldwide approx-
imately 260 million people are chronic HBV (CHB) sur-
face antigen (HBsAg) carriers and current treatment with 
interferon and/or nucleoside analogues (NA) is not able 
to achieve a complete cure (EASL, 2017; Schweitzer et 
al., 2015). The key obstacle to HBV eradication is the per-
sistence of HBV DNA in the nuclei of infected hepatocytes, 
either integrated into the host genome or as a covalently 
closed circular DNA (cccDNA) episomal form (Allweiss 
and Dandri, 2017; Summers and Mason, 2004). While 
HBV integration is rare and its clinical implications still 
require investigation (Tu et al., 2017), cccDNA plays an 
essential role in the long-term persistence of HBV infec-
tion and can often be detected even following NA therapy 
and HBsAg seroconversion (Boyd et al., 2016; EASL, 2017; 
Lai et al., 2017; Singh et al., 2004). Since quantification of 
cccDNA in infected hepatocytes (Lenci et al., 2010; Luo 
et al., 2016; Werle–Lapostolle et al., 2004) requires inva-
sive liver biopsy, more accessible tissues, such as serum or 
peripheral blood mononuclear cells (PBMCs), have been 




©2018 by EDIMES - Edizioni Internazionali Srl. All rights reserved
using non-standardized techniques (Chen et al., 2004; Li 
et al., 2017). Some reports have shown that cccDNA in 
patients’ sera is a marker of off-treatment virological re-
lapse (Chen et al., 2004; Singla et al., 2014; Takkenberg et 
al., 2009), whereas others have not found cccDNA in the 
serum of CHB patients (Jun-Bin et al., 2003; Köck et al., 
1996; Werle–Lapostolle et al., 2004). Some investigators 
speculate that PBMCs support HBV replication only par-
tially, with linear and circular relaxed HBV DNA but not 
cccDNA formed in these cells (Köck et al., 1996; Laskus 
et al., 1999; Murakami et al., 2004; Umeda et al., 2005), 
while others have detected cccDNA in PBMCs and/or 
plasma (Cabrerizo et al., 2000; Coffin et al., 2015, 2014; 
Mazet-Wagner et al., 2006; Pasquinelli et al., 1990; Torii et 
al., 2003) in a variable proportion of patients with chronic 
and occult HBV infection. Discrepancies in HBV distribu-
tion and compartmentalization were observed according 
to the serologic profile or the coinfection status of patients 
analysed (Coffin et al., 2015; Loustaud-Ratti et al., 2013). 
While HCV coinfection seems not to be associated with a 
different distribution of tDNA and cccDNA in serum and/
or PBMCs of HBV positive patients, independently of their 
serological profile, HIV-1 seropositivity seems to influence 
the distribution of tDNA, which is prevalently detected 
in serum with respect to PBMCs in HBcAg positive and 
HBsAg negative patients. This profile suggests that HIV-in-
duced immune dysfunction results in the maintenance of 
a low HBV viral load (Wagner et al., 2004).
We developed molecular methods to evaluate the distribu-
tion of total HBV DNA (tDNA) and cccDNA in plasma and 
PBMCs of patients with low or undetectable HBV viremia. 
Written informed consent was obtained from each patient 
Key words:
HBV, cccDNA, Real time PCR, PBMC
SUMMARY
Few studies have documented hepatitis B virus (HBV) DNA in peripheral blood mononuclear cells (PB-
MCs). We developed real-time PCR methods for differential amplification of covalently closed circular 
(cccDNA) and total HBV DNA (tDNA). The different distribution of cccDNA and tDNA in plasma and 
PBMCs was evaluated in 37 patients with low or undetectable viremia. Plasma tDNA measured by the 
Abbott reference system and the in-house assay correlated well (Spearman rho = 0.804; P<0.0001). tDNA 
was detected in four PBMC samples, all from patients with detectable plasma viremia (range 633-6,406 IU/
ml), cccDNA was not detected in any sample. The reasons for apparently discrepant results need further 
investigation but possibly include the high diversification of HBV status and plasma viremia levels. 
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included in the study. The study protocol conforms to the 
ethical guidelines of the 1975 Declaration of Helsinki (7th 
revision, 2013) as reflected in a priori approval by the in-
stitutional human ethics committee. Plasma tDNA was 
quantified using the certified Abbott Real-time HBV Viral 
Load Assay (Abbott Diagnostics Inc.). HBsAg, HBeAg, an-
ti-HBs, anti-HBe were detected by using the Elecsys sys-
tem (Roche Diagnostics, Italy).
PBMCs and plasma were isolated from 8 ml of blood us-
ing Ficoll gradient centrifugation (Pharmacia) and stored 
frozen until used. Before collection, PBMC pellets were 
washed twice with phosphate-buffered saline (PBS) to re-
move viral particles possibly adsorbed on the cell mem-
brane. Viral DNA was extracted from 200 µl of plasma or 
all the stored PBMCs preparation using the High Pure Viral 
Nucleic Acid Kit (Roche) according to the manufacturer’s 
instructions. Real-time quantitative PCR (qPCR) methods 
for differential amplification of cccDNA and tDNA in plas-
ma and PBMCs samples were developed. Briefly, cccDNA 
was preferentially amplified with specific primers flanking 
the gap region and the incomplete strand of HBV DNA 
while tDNA primers detected all forms of HBV DNA, in-
cluding relaxed circular forms and cccDNA (Table 1). The 
beta-globin gene was simultaneously targeted in the tDNA 
qPCR performed on PBMCs to estimate the number of 
cells in each PCR reaction. The HBV qPCR standard curve 
was generated using serial 10-fold dilutions of a plasmid 
carrying a 1,000-bp fragment of HBV genome and normal-
ized on the calibration curve of the International WHO 
linear HBV DNA Standard (NIBSC code 10/264). Similar-
ly, the beta-globin standard curve was generated using hu-
man DNA derived from Sup-T1 cells (AIDS Reagent Pro-
gram catalog number 100). The tDNA qPCR reaction mix-
ture included 750 ng of spectrophotometrically measured 
PBMCs DNA or 5 µl of plasma DNA, 10 µl Premix Ex Taq 
(Takara Bio), 7.5 pmol of each of tDNA and beta-globin 
primers and 2.5 pmol of each of the tDNA universal probe 
and beta-globin probe in a final volume of 20 µl. Nega-
tive controls for qPCR and DNA extraction were included 
in each run, and each sample was amplified in duplicate. 
To improve the specificity of cccDNA detection, 2 µg of 
PBMCs DNA and plasma viral DNA were digested with 
10 Units of Plasmid Safe DNase (Epi centre) for 1 hour at 
37°C, as indicated by the manufacturer. This step was per-
formed to destroy the single stranded DNA isolated from 
PBMCs and plasma prior to cccDNA detection. The cccD-
NA qPCR reaction mixture included 5 µl of digested DNA, 
10 µl Premix Ex Taq (Takara Bio), 2% of DMSO, 7.5 pmol 
each of cccDNA primers and 2.5 pmol of tDNA universal 
probe in a final volume of 20 µl. All the reactions were run 
in a Light Cycler 96 system (Roche) for 50 cycles each in-
cluding 15 seconds at 95°C and 1 minute at 57°C after the 
first denaturation step (5 minutes at 95°C). Data acquisi-
tion and handling were carried out using the Light Cycler 
96 Software version 1.1.0.1320. 
The association between tDNA values obtained with 
the Abbott Reference System and the in-house qPCR in 
plasma samples was evaluated by Spearman correlation 
analysis. The correlation between qPCR tDNA values 
and HbeAg status or HBV genotype were analysed by the 
Mann-Whitney test.
The limit of detection of qPCR was 10 IU/ml of plasma 
and 60 copies/106 PBMCs for tDNA and 5 IU/ml of plas-
ma and 30 copies/106 PBMCs for cccDNA. The coefficient 
Table 1 - Primers and probe sequences used for tDNA and cccDNA differential amplification in qPCR system. Coordinates 
are referred to X02763 HBV genotype A used as reference sequence (https://hbvdb.ibcp.fr/HBVdb/HBVdbNomenclature).
Primer Sequence (5’ – 3’) Coordinates Labelling Direction Target
P783 GTCTGTGCCTTCTCATCTGC 1551-1570 NO Forward cccDNA only




P785 GCAACTTTTTCACCTCTGCCTA 1816-1837 NO Forward tDNA






Table 2 - Baseline characteristics of the 37 patients included 
in the study. 
Population  
characteristics
Values expressed as n (%),  
except* median (Inter Quartile Range)
Patient Data
Age, years 48.4* (37.8-60.5)
Gender, males 26 (70)
Caucasian ethnicity 27 (73)
Time from diagnosis 
of infection
7.3 (4.9-13.8)
HIV coinfection 2 (5.4)










Genotype D 19 (68) A 6 (21), E 2 (7), B 1 (4)
HBV DNA Undetectable 15 (40.5)
HBV DNA <10 IU/ml 5 (13.5)
HBV DNA ≥10 IU/ml 17 (46)
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of variability (CV) of the Ct values ranged from 5.55% to 
1.37% for tDNA qPCR and 2.04% to 1.00% for cccDNA 
qPCR when measuring 5 to 50,000 plasmid target copies, 
with a linear dynamic range covering the 5 log10. The ef-
ficacy and safety of the Plasmid Safe DNase protocol was 
confirmed by a complete loss of PCR signal following 
treatment of 5,000-50,000 IU of the International linear 
HBV DNA Standard and no measurable loss of PCR signal 
following treatment of 5,000-50,000 IU of the HBV plas-
mid, respectively. 
The baseline characteristics of the 37 patients recruited 
for the study are listed in Table 2. Plasma tDNA quanti-
fied with the Abbott reference system was undetectable 
in 15 samples, detectable below 10 IU/ml in five samples 
and above 10 IU/ml in 17 (median tDNA levels 336 IU/
ml, IQR 69-793). Plasma tDNA levels measured by the 
Abbott reference system and the in-house qPCR correlat-
ed well (Spearman rho = 0.80; P<0.0001), with mean±SD 
difference 0.20±0.62 log10 IU/ml (Figure 1). Discordant 
results (bias of tDNA quantification larger than one log) 
were obtained only in 6 (16.2%) patients. Plasma tDNA 
levels showed no apparent association with HBeAg status 
(P=0.588) or HBV genotype (P=0.371). In the two HIV-1 
coinfected patients, tDNA was below the limit of detection 
in plasma and PBMC samples. tDNA was detected in four 
PBMC samples, with values of 1,963, 2,017, 3,609, and 
26,868 copies per 106 PBMCs, all from patients with de-
tectable plasma viremia (range 633-6,406 IU/ml). Of note, 
a control cccDNA qPCR performed before digestion with 
Plasmid Safe DNase scored positive in 13.5% of samples 
(2 plasma and 3 PBMCs). However after enzymatic treat-
ment, cccDNA was not confirmed in any sample, suggest-
ing that the digestion step must be included in cccDNA 
detection protocols. 
Figure 1 - Correlation between in-house qPCR and Abbott 
HBV viral load assay (Roche Diagnostics) in the plasma of 
37 patients with low or undetectable HBV viremia.
Quantitative analysis of residual HBV DNA replication 
can be useful when assessing the risk of reactivation in 
patients with occult infection or “inactive” HBsAg car-
riers, or in order to determine the potential for HBV 
transmission in donor individuals and the efficacy of 
treatment regimens on HBV reservoirs. While cccDNA 
can be detected in liver biopsies as the key HBV repli-
cative form, less invasive blood markers have been pro-
posed including quantitative HBsAg (Wong et al., 2017) 
and the Hepatitis B core-related antigen (HBcrAg) (Park 
et al., 2012). However, these markers do not appear to 
be completely representative of cccDNA levels reflecting 
only partially the amount of HBV DNA and cccDNA in 
hepatocytes (Honda et al., 2016). Quantitation of cccD-
NA in blood is an attractive option but it remains contro-
versial whether extrahepatic tissues contain cccDNA and 
whether cccDNA is released into the serum. This hypoth-
esis is supported by HBV re-activation after orthotopic 
liver transplantation (Takaki et al., 2015). 
In the small patient group with low to undetectable plas-
ma tDNA levels analysed in our study, we detected no 
cccDNA in plasma and PBMCs while tDNA was detected 
only in a few cases in the PBMC compartment, all associ-
ated with measurable plasma HBV DNA. Several (Cabre-
rizo et al., 2000; Coffin et al., 2014; Loustaud-Ratti et al., 
2013; Stoll-Becker et al., 1997; Torii et al., 2003), but not all 
(Köck et al., 1996; Mazet-Wagner et al., 2006; Umeda et al., 
2005), studies previously documented tDNA and occasion-
ally cccDNA in a proportion of patients with chronic and 
occult HBV infection. Our case file included low viremic 
patients and thus complements previous studies, support-
ing the concept that PBMC tDNA and cccDNA are mostly 
associated with the OBI profile as recently reviewed (Joshi 
and Coffin, 2018). As suggested by our own control ex-
periments, the lack of PBMCs/plasma pre-treatment with 
a DNase to digest the relaxed circular form of the HBV 
genome could explain the overestimation of cccDNA in 
some studies (Cabrerizo et al., 2000; Takkenberg et al., 
2009; Torii et al., 2003). Indeed, it must be emphasized 
that methods for cccDNA detection are far from standard. 
Other reasons for the discrepancy with previous literature 
may be related to the high diversification of patient popu-
lation analysed in terms of infection status (e.g. inactive/
active carriers or occult infection), plasma viremia levels 
and the proportion of treated patients. The prevalence and 
role of blood cccDNA remains elusive, suggesting analysis 
of a large and comprehensive HBV population with a stan-
dardized method.
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